Actor portrayal.
FDA APPROVED FOR THE TREATMENT OF ADULTS AND ADOLESCENTS (AGED ≥12) WITH ATOPIC DERMATITIS
Itch relief like that
NEMLUVIO relieves itch fast
with skin healing that lasts1,2
A novel, IL-31RA–targeted biologic that delivers itch relief as soon as 48 hours* in some patients, and helps block the urge to scratch, so patients can experience skin healing that lasts1‑4
PP-NRS response was achieved at 48 hours in 10.7% of patients with NEMLUVIO +TCS/TCI vs 2.9% with placebo +TCS/TCI. Data are from pooled post-hoc analysis of daily PP‑NRS improvement reported in Phase 3 clinical studies (ARCADIA 1 and ARCADIA 2). PP‑NRS response defined as a ≥4‑point improvement from baseline. No conclusions regarding efficacy should be made based on these results.1
NOW THE FASTEST GROWING BIOLOGIC FOR ATOPIC DERMATITIS||
For ages 12 and up.
Measuring JAN-OCT 2025 compounded growth rate using IQVIA NPA data with indication factoring for both Nemluvio (SP & HUB data) and competitors (IQVIA LAAD).
NEMLUVIO Unique Mechanism of Action3,4
NEMLUVIO® is the first and only neuroimmune-targeted treatment to directly block IL-31RA—blocking the signaling that drives itch, inflammation, skin barrier dysfunction, and fibrosis3,4
Lasting Skin Healing2
At Week 16, 44% of patients achieved significant clearance (EASI-75) vs 29% with placebo† and 36% of patients taking NEMLUVIO + TCS/TCI achieved clear (IGA 0) or almost clear (IGA 1) skin vs 25% with placebo3†
More than 8 out of 10 patients achieved skin clearance with 2 years of treatment2‡
Fast Itch Relief1
Significant relief was achieved as soon as 48 hours* in some patients. Consistent results were seen in ARCADIA 1 and ARCADIA 21
PP-NRS response was achieved at 48 hours in 10.7% of patients with NEMLUVIO +TCS/TCI vs 2.9% with placebo +TCS/TCI. Data are from pooled post-hoc analysis of daily PP‑NRS improvement reported in Phase 3 clinical studies (ARCADIA 1 and ARCADIA 2). PP‑NRS response defined as a ≥4‑point improvement from baseline. No conclusions regarding efficacy should be made based on these results.1
Favorable Safety Profile3
NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring3
Q4W Dosing From the Start3
NEMLUVIO offers the convenience of less frequent dosing for patients with AD when compared to dupilumab3,5
Real dermatologists and patients agree: NEMLUVIO relives itch fast with skin healing that lasts1,2*‡
Hear Dr. Murase and her patient Karen talk about the transformative impact of NEMLUVIO in the real world.
Atopic dermatitis is a disease of the whole skin. It's not something that you can just give a tube and then see somebody months later. You need to treat the itch. You need to treat the inflammation. You need to treat the skin barrier. And the wonderful thing about NEMLUVIO is it does all three of those things.
Hello, my name is Doctor Jenny Murase. I'm a dermatologist who practices in Northern California, and I run a medical consultative clinic for patients that have bad rash and bad itch. So I take care of a ton of patients with atopic dermatitis as well as prurigo nodularis.
You never know when all of a sudden, they're going to get this intense episode of 10 out of 10 itching. They don't know when it's going to happen. There's a loss of the sense of control of your life. There's the loss of really being able to function, and it's so hard because they hold it in silence. That it's something that is not visible. Itch isn't visible ... It really is something that could be dismissed so easily.
So within the last three and a half years is when I started the journey on this. These rashes that were different and covering my back and my arms and my legs.
I was getting to the point where I was losing hope if I couldn't meet a doctor that could diagnose me and help me with some kind of medication.
I think that in Karen's case, she definitely is a patient that has atopic dermatitis. She has asthma, and we actually call this the atopic triad, so she has asthma, hay fever, and eczema. And those conditions, they run together.
Mentally, I mean, it consumed my thoughts from the time I went to bed until I had ice packs on my back to fall asleep. And then in the morning, you know, I would itch because those were super warm now, because they had melted.
It really affected like our daily activities on the weekend and what we decided to do if the weather was hot or trips that we took, we didn't want to go to certain places when it was going to be too hot and humid because I was so uncomfortable.
You know, it’s severe atopic dermatitis that's affecting their ability to function ...
And because I had a therapeutic that really was able to address that itch quickly and effectively, it changed their lives.
She said that she thought that the NEMLUVIO would really change me, and it has.
Some patients are seeing significant itch reduction as soon as 48 hours.
Pretty quickly within a few days. I was feeling so much better in so many ways, not just my rash, not just the itch, but my daily life and what I thought about.
So it has impacted me, and I didn't realize how much it had until I started feeling better and realized, wow, I can go, you know, to the pool with the kids now and get in the water. Get in the hot tub with them if I want to and not worry about where we're traveling, you know.
NEMLUVIO has had a dramatic impact on my ability to care for patients that have bad itch and bad rash the past several months since I've had access to this medication.
There are a lot of patients out there, people out there that are suffering ... So I want everyone to know that, you know, you don't have to suffer through it.
At first, when NEMLUVIO became available, I was so excited to have a therapeutic that would really effectively treat itch quickly.
After taking NEMLUVIO, I feel much more confident with my skin.
Your real-time navigation partner to help patients start and stay on NEMLUVIO
GPS (Galderma Patient Services) for NEMLUVIO™ offers:
- Access to assistance programs and adherence support
- Nursing support for injection training and product education
For any questions or to learn how to enroll in GPS for NEMLUVIO, please call 1-855-NEMLUVIO, 8:00 AM - 8:00 PM ET, Monday‑Friday
Sign up now for more information about NEMLUVIO for AD
Data shown from ARCADIA 1 full population analysis; consistent results seen in ARCADIA 2.
EASI-75 data of patients reaching 56 weeks during interim analysis of ARCADIA LTE.
AD=atopic dermatitis; EASI=Eczema Area and Severity Index; IGA=Investigator Global Assessment; IL-31RA=interleukin-31 receptor alpha; LTE=long-term extension; PP-NRS=Peak Pruritus Numerical Rating Scale; Q4W=every 4 weeks; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.
References: 1. Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025;00:1‑9. doi:10.1111/jdv.70250 2. Augustin M, Tauber M, Sidbury R, et al. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2025;00:1–15. doi:10.1111/jdv.70080 3. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 4. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097 5. DUPIXENT Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc.; 2024.